Steroid hormone receptors in breast cancer management
暂无分享,去创建一个
[1] G. Greene,et al. Immunochemical studies of estrogen receptors. , 1984, Journal of steroid biochemistry.
[2] P. Meltzer,et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. , 1997, Science.
[3] H. Dotzlaq. Expression of Estrogen Receptor- in Human Breast Tumors , 1997 .
[4] W. McGuire,et al. Predicting response to endocrine therapy in human breast cancer: a hypothesis. , 1975, Science.
[5] Å. Borg,et al. An exon 5 deletion variant of the estrogen receptor frequently coexpressed with wild-type estrogen receptor in human breast cancer. , 1993, Cancer research.
[6] W. McGuire. Estrogen receptors in human breast cancer. , 1973, The Journal of clinical investigation.
[7] N. Gibbon. CURE OF EARLY SYPHILIS. , 1963, Lancet.
[8] W. McGuire,et al. Multiple estrogen receptor assays in human breast cancer. , 1983, Cancer research.
[9] R. Simon,et al. Association between steroid hormone receptor status and disease-free interval in breast cancer. , 1979, Cancer treatment reports.
[10] Helmut Dotzlaw,et al. Expression of estrogen receptor-beta in human breast tumors. , 1997, The Journal of clinical endocrinology and metabolism.
[11] W. McGuire,et al. Estrogen receptor status as a prognostic indicator for stage I breast cancer patients , 2005, Breast Cancer Research and Treatment.
[12] R. Schmutzler,et al. An estrogen receptor genetic polymorphism and a history of spontaneous abortion — Correlation in women with estrogen receptor positive breast cancer but not in women with estrogen receptor negative breast cancer or in women without cancer , 2004, Breast Cancer Research and Treatment.
[13] D. McDonnell,et al. The A and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cells , 1994, Molecular and cellular biology.
[14] J. Gustafsson,et al. Cloning of a novel receptor expressed in rat prostate and ovary. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[15] A. Walt,et al. The surgical implications of estrophile protein estimations in carcinoma of the breast. , 1976, Surgery.
[16] W. McGuire,et al. Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. , 1992, Cancer research.
[17] R. Blamey,et al. Relationship between oestrogen-receptor content and histological grade in human primary breast tumours. , 1978, British Journal of Cancer.
[18] M. Lippman,et al. Quantitative estrogen receptor analyses: The response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease‐free interval , 1980, Cancer.
[19] R. Simon,et al. The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. , 1978, The New England journal of medicine.
[20] S. Cowley,et al. Estrogen Receptors α and β Form Heterodimers on DNA* , 1997, The Journal of Biological Chemistry.
[21] K. Horwitz,et al. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. , 1997, Molecular endocrinology.
[22] B. O’Malley,et al. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. , 1997, Molecular endocrinology.
[23] K. Grandien,et al. Printed in U.S.A. Copyright © 1997 by The Endocrine Society Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors � and � , 2022 .
[25] G. Greene,et al. Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells , 1984, Nature.
[26] C. Osborne,et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] R. Blamey,et al. Steroid receptors in early breast cancer: value in prognosis. , 1981, Journal of steroid biochemistry.
[28] D. McDonnell,et al. RU486 exerts antiestrogenic activities through a novel progesterone receptor A form-mediated mechanism. , 1994, The Journal of biological chemistry.
[29] R. Hähnel,et al. Prognostic value of estrogen receptors in primary breast cancer , 1979, Cancer.
[30] N. Copeland,et al. Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. , 1997, Molecular endocrinology.
[31] W. McGuire,et al. The value of estrogen and progesterone receptors in the treatment of breast cancer , 1980, Cancer.
[32] D. Allred,et al. Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance. , 1990, Archives of surgery.
[33] G. T. Budd,et al. Estrogen receptor mutations in tamoxifen-resistant breast cancer. , 1994, Cancer research.
[34] H. Gronemeyer,et al. Transcription activation by estrogen and progesterone receptors. , 1991, Annual review of genetics.
[35] E. Jensen,et al. Mechanism of action of the female sex hormones. , 1972, Annual review of biochemistry.
[36] W. McGuire,et al. Hormone receptors in primary and advanced breast cancer. , 1980, Clinics in endocrinology and metabolism.
[37] J. Polman,et al. ERβ: Identification and characterization of a novel human estrogen receptor , 1996 .
[38] K Griffiths,et al. RELATIONSHIP OF ŒSTROGEN-RECEPTOR STATUS TO SURVIVAL IN BREAST CANCER , 1979, The Lancet.
[39] K. Horwitz,et al. Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors. , 1993, Molecular endocrinology.
[40] E. J. Gregory,et al. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. , 1977, Cancer research.
[41] Thorsten Heinzel,et al. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor , 1995, Nature.
[42] D. Berry,et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. , 1994, The New England journal of medicine.
[43] C. Redmond,et al. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] Mike Clarke,et al. Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[45] W. McGuire,et al. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] S. Aamdal,et al. Estrogen receptors and long‐term prognosis in breast cancer , 1984, Cancer.
[47] P. Webb,et al. Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. , 1995, Molecular endocrinology.
[48] C. Vogel. Adjuvant systemic therapy of primary breast cancer , 1988 .
[49] R. Millis. Correlation of hormone receptors with pathological features in human breast cancer , 1980, Cancer.
[50] K. Horwitz,et al. Nuclear receptor coactivators and corepressors. , 1996, Molecular endocrinology.
[51] B. Katzenellenbogen,et al. The carboxy-terminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists. , 1995, Molecular endocrinology.
[52] R. Blamey,et al. QUANTITATIVE OESTRADIOL RECEPTOR VALUES IN PRIMARY BREAST CANCER AND RESPONSE OF METASTASES TO ENDOCRINE THERAPY , 1981, The Lancet.
[53] D. Chalbos,et al. Differential effect of forms A and B of human progesterone receptor on estradiol-dependent transcription. , 1994, The Journal of biological chemistry.
[54] Mike Clarke,et al. Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[55] S. Schreiber,et al. Nuclear Receptor Repression Mediated by a Complex Containing SMRT, mSin3A, and Histone Deacetylase , 1997, Cell.
[56] C. Glass,et al. Nuclear receptor coactivators. , 1997, Current opinion in cell biology.
[57] K. Mccarty,et al. Elastosis in human breast cancer. Correlation with sex steroid receptors and comparison with clinical outcome. , 1984, Archives of pathology & laboratory medicine.
[58] S. Fuqua,et al. A role for estrogen-receptor variants in endocrine resistance , 1995 .
[59] Predicting response to endocrine therapy in human breast cancer: a hypothesis. , 1976, Science.
[60] J. Gorski,et al. Hormone receptors: studies on the interaction of estrogen with the uterus. , 1968, Recent progress in hormone research.
[61] H. Westerberg,et al. Estrogen receptor level and other factors in early recurrence of breast cancer , 1980, International journal of cancer.
[62] E. J. Gregory,et al. Correlation of primary breast cancer histopathology and estrogen receptor content , 1981, Breast Cancer Research and Treatment.
[63] W. McGuire,et al. Multiple progesterone receptor assays in human breast cancer. , 1984, Cancer research.
[64] S. Hilsenbeck,et al. The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth , 2004, Cancer Chemotherapy and Pharmacology.
[65] D. Kiang,et al. Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer. , 1978, The New England journal of medicine.
[66] Teri Oldaker,et al. DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients , 1993, Breast Cancer Research and Treatment.
[67] H. Rockette,et al. Correlation of estrogen receptor and pathologic characteristics of invasive breast cancer , 1980, Cancer.
[68] W. McGuire,et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] Hui Li,et al. Characterization of receptor interaction and transcriptional repression by the corepressor SMRT. , 1997, Molecular endocrinology.
[70] J. Meyer,et al. Low incidence of estrogen receptor in breast carcinomas with rapid rates of cellular replication , 1977, Cancer.
[71] R. Paridaens,et al. Clinical significance of the quantitative assessment of estrogen receptors in advanced breast cancer , 1980, Cancer.
[72] C. D. HAAGENSEN,et al. Diseases of the Breast , 1972 .